A Randomized, Double-blind, Placebo-controlled, Ascending Dose, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intravenous and Subcutaneous Doses of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Ascending Dose, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intravenous and Subcutaneous Doses of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs SHP 623 (Primary) ; SHP 623 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions
  • Sponsors Shire
  • Most Recent Events

    • 09 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 02 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 28 Mar 2016 Status changed from not yet recruiting to recruiting as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top